ExaGrid Wins 2 New Industry Awards at the Storage Awards
MARLBOROUGH, Mass. — ExaGrid ®, the industry's only Tiered Backup Storage solution with Retention Time-Lock and the only non-network-facing tiered air gap with delayed deletes and immutability for ransomware recovery, today announced that the company was honored with two awards, Channel Partner Programme and Storage Company of the Year, during the 22 nd annual Storage Awards ceremony, 'The Storries,' held in London on June 5, 2025.
Article content
The Storage Awards are determined by public vote. The 2025 awards mark the 14 th year of wins for ExaGrid at 'The Storries.' The Channel Partner Programme award recognizes the innovative ExaGrid Reseller Partner Program, which is designed to be easy for partners with support from the ExaGrid sales team and without milestone commitments. ExaGrid is known for having a Tiered Backup Storage system that 'just works,' is not oversold or undersized, and provides its customers with the best customer support industry from an assigned level 2 technical support engineer, ensuring that partners' customers are well taken care of.
Article content
The Storage Company of the Year award recognizes ExaGrid's unique Tiered Backup Storage product line, which offers the largest single scale-out system in the industry that includes data deduplication, that fastest backups and restores to keep users productive, and comprehensive security with ransomware recovery.
Article content
ExaGrid continues to gain recognition for its Tiered Backup Storage, winning six industry awards so far in 2025, including:
Article content
Data Breakthrough Awards – Data Backup Solution of the Year
Network Computing Awards – Air-gapped Ransomware Recovery Product of the Year
Network Computing Awards – Company of the Year
Network Computing Awards – Storage Product of the Year
Storage Awards – Channel Partner Programme
Storage Awards – Storage Company of the Year
Article content
'We are honored to win Channel Partner Programme and Storage Company of the Year, ' said Bill Andrews, President and CEO of ExaGrid. 'Thank you to everyone who voted for us, we are grateful to our partners and customers for their support, and for the continued recognition of our team, our programs, and our Tiered Backup Storage product line.'
Article content
About ExaGrid
Article content
ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, scale-out architecture, and comprehensive security features. ExaGrid's Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The Repository Tier offers the lowest cost for long-term retention. ExaGrid's scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and planned product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier (tiered air gap), delayed deletes, and immutable objects to recover from ransomware attacks.
Article content
ExaGrid has physical sales and pre-sales systems engineers in the following countries: Argentina, Australia, Benelux, Brazil, Canada, Chile, CIS, Colombia, Czech Republic, France, Germany, Hong Kong, India, Israel, Italy, Japan, Mexico, Nordics, Poland, Portugal, Qatar, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Turkey, United Arab Emirates, United Kingdom, United States, and other regions.
Article content
Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup storage in our customer success stories. ExaGrid is proud of our +81 NPS score!
Article content
Article content
Article content
Article content
Media:
Article content
Mary Domenichelli
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
a day ago
- CTV News
$10K in damages after morning residential fire
The London Fire Department attended a residential fire in the 200 block of Middleton Avenue on Aug. 15, 2025. (Source: London Fire Department) Early Friday morning, the London Fire Department attended a residential fire in the 200 block of Middleton Avenue. Fire crews were able to contain the fire, and officials say early detection due to working smoke alarms prevented serious injury. The damage is estimated at $10,000. LFD is reminding residents that charging devices on soft surfaces can overheat and cause fires.
Globe and Mail
2 days ago
- Globe and Mail
Smith & Nephew (SN) Receives a Hold from Stifel Nicolaus
Stifel Nicolaus analyst Dylan Van Haaften maintained a Hold rating on Smith & Nephew today and set a price target of £14.15. The company's shares closed today at p1,353.00. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Van Haaften covers the Healthcare sector, focusing on stocks such as Merck KGaA, Smith & Nephew, and Sartorius. According to TipRanks, Van Haaften has an average return of -5.5% and a 32.65% success rate on recommended stocks. In addition to Stifel Nicolaus, Smith & Nephew also received a Hold from Berenberg Bank's Sam England in a report issued on August 11. However, yesterday, Bank of America Securities reiterated a Buy rating on Smith & Nephew (LSE: SN). SN market cap is currently £11.76B and has a P/E ratio of 30.99. Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SN in relation to earlier this year.
Globe and Mail
2 days ago
- Globe and Mail
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs
AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 43% of AstraZeneca's total revenues) rose 18% in the second quarter of 2025, generating $6.3 billion in sales. In the first half of 2025, the Oncology segment generated almost $12 billion in revenues, which rose 16% year over year. The strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca also has a profit-sharing deal with Merck MRK for Lynparza. AstraZeneca is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates. A key new cancer drug approval was that of Truqap for HR-positive, HER2-negative (HR+ HER2-) breast cancer. The drug has seen a robust launch, recording sales of $302 million in the first half of 2025, driven by demand growth in the second-line biomarker-altered population. AstraZeneca expects further growth for Truqap to be driven by increased uptake within the PIK3CA population and additional global launches. AstraZeneca and partner Daiichi's drug, Datroway, was approved by the FDA for HR+ HER2- breast cancer in January and for EGFR-mutated non-small cell lung cancer (NSCLC) in June this year. Datroway witnessed encouraging early launch signals in the United States for the breast cancer indication in the first half, recording sales of $14 million. Important late-stage oncology candidates in AstraZeneca's pipeline are camizestrant (HR+ HER2- metastatic breast cancer), volrustomig (several types of cancers), sonesitatug vedotin (advanced or metastatic gastric or GEJ adenocarcinoma) and surovatamig (previously untreated follicular lymphoma). Regulatory applications seeking approval of Imfinzi for early-stage gastric and gastroesophageal junction cancers are under regulatory review. AstraZeneca expects continued growth of its oncology medicines in the second half, particularly Tagrisso, Enhertu, and Merck-partnered Lynparza and Imfinzi, despite the incremental impact of the Part D redesign. Our estimates for AstraZeneca's total oncology portfolio suggest a CAGR of around 11.1% over the next three years. Competition in the Oncology Space Other large players in the oncology space are Pfizer PFE, Merck and Bristol-Myers BMY. Pfizer boasts a strong portfolio of approved cancer medicines like Xtandi, Lorbrena, and the Braftovi-Mektovi combination. Pfizer's oncology revenues grew 9% in the first half of 2025. The addition of Seagen in 2023 also strengthened its position in oncology by adding four antibody-drug conjugates (ADCs) — Adcetris, Padcev, Tukysa and Tivdak. Pfizer also has a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, ADCs and immuno-oncology biologics. Merck's key oncology medicines are PD-L1inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Keytruda's sales rose 6.6% to $15.1 billion in the first half of 2025. Bristol-Myers' key cancer drug is PD-L1inhibitor, Opdivo, which accounts for around 20% of its total revenues. Opdivo's sales rose 9% to $4.82 billion in the first half of 2025. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report
